-
Mashup Score: 2
Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2
During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder cancer.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
During a live event, Matthew Galsky, MD, (@MattGalsky) discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder cancer. #blcsm | @IcahnMountSinai @TischCancer https://t.co/zlByjDKsr7
-
-
Mashup Score: 5
The objectives of the trial are to further confirm the recommended phase 2 dose and to assess the efficacy of MVR-T3011.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The first patient has been dosed in a phase 2 trial investigating MVR-T3011, an oncolytic immunotherapy for patients with BCG-unresponsive high-risk NMIBC. @VigneshPackiam #blcsm https://t.co/9n2ZQQXu0O
-
-
Mashup Score: 6Real-World Data Help Fill the Gaps Left by Clinical Trial Results in Urothelial Carcinoma - 24 day(s) ago
David J. Benjamin, MD, discusses how he uses real-world data to supplement clinical trial results in urothelial carcinoma.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Real-World Data Help Fill the Gaps Left by Clinical Trial Results in Urothelial Carcinoma @DavidBenjaminMD #blcsm https://t.co/XTaOwoc3t2
-
-
Mashup Score: 5
Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management @PGrivasMDPhD @fredhutch #blcsm https://t.co/meL8r1lUHT
-
-
Mashup Score: 5
Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management @PGrivasMDPhD @fredhutch #blcsm https://t.co/meL8r1lUHT
-
-
Mashup Score: 0Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC - 1 month(s) ago
Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer. #blcsm https://t.co/SA5heKrM8X
-
-
Mashup Score: 4Biomarker Testing Expands in Metastatic Bladder Cancer - 1 month(s) ago
Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
In an interview with Targeted Oncology, Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer. #blcsm | @OntadaOncology https://t.co/5TEpJNcIs4
-
-
Mashup Score: 4
Disitamab vedotin plus toripalimab showed significant survival benefits vs chemo in first-line HER2+ advanced urothelial carcinoma, with a manageable safety profile.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
Statistically significant and clinically meaningful PFS and OS benefits were seen with disitamab vedotin + toripalimab vs standard chemo when used as a first-line treatment for patients with HER2+ locally advanced/metastatic urothelial carcinoma. #blcsm https://t.co/Ioo53azwc5
-
-
Mashup Score: 0Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC - 2 month(s) ago
Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
After 1 year of treatment, durvalumab + BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in DFS vs BCG therapy alone in BCG-naïve, high-risk NMIBC who had undergone prior TURBT. #blcsm https://t.co/CmLOelrxVx https://t.co/JCiv4ugYWG
-
Anne Schuckman, MD, (@AnneSchuckmanMD) discusses the growing number of options in NMIBC and describes the impact of this innovation for clinical practice. @USC_Urology #blcsm https://t.co/QwD2jVIbVv